In contrast, targeting Stat3 in myeloid cells using our CpG-conjugated siRNA sufficiently reverses insulin resistance in vivo, supporting the idea that selective inhibition of Jak2 or Stat3 in myeloid cells may offer a safer and more specific therapeutic approach for treating obesity-related insulin resistance. The gene discussed is JAK2; the disease is obesity due to melanocortin 4 receptor deficiency.